83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2
View the complete AFFIRM study description.
aAs of January 2020.3
Stephen Newman, MD, and patient Jennifer discuss evidence from the clinical trial as it relates to their own experiences with TYSABRI.